52 studies found for:    gdc-0449
Show Display Options
Rank Status Study
1 Active, not recruiting Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue light
2 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
3 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
4 Completed GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
6 Active, not recruiting Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Active, not recruiting The Purpose of This Study is to Determine The Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Conditions: Basal Cell Nevus Syndrome;   Gorlin Syndrome
Intervention: Drug: GDC-0449
8 Completed GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: vismodegib;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
9 Unknown  Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
10 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
11 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
12 Not yet recruiting A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Condition: Prostate Cancer
Intervention: Drug: Vismodegib
13 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Drug: vismodegib;   Other: pharmacological study
14 Active, not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Other: diagnostic laboratory biomarker analysis
15 Active, not recruiting
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib 150 mg
16 Recruiting Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Diffuse Large B-cell Lymphoma;   "Indolent" Non-hodgkin Lymphoma;   Primary Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Vismodegib
17 Active, not recruiting Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: vismodegib;   Other: hydrocortisone/placebo;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: flow cytometry;   Other: enzyme-linked immunosorbent assay;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
18 Active, not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis
19 Active, not recruiting Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Active, not recruiting Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Drug: vismodegib;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years